LTRN vs. RVPH, ACRS, ONCY, BTAI, VERU, ELYM, AFMD, ENLV, IFRX, and RZLT
Should you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Reviva Pharmaceuticals (RVPH), Aclaris Therapeutics (ACRS), Oncolytics Biotech (ONCY), BioXcel Therapeutics (BTAI), Veru (VERU), Eliem Therapeutics (ELYM), Affimed (AFMD), Enlivex Therapeutics (ENLV), InflaRx (IFRX), and Rezolute (RZLT). These companies are all part of the "pharmaceutical preparations" industry.
Reviva Pharmaceuticals (NASDAQ:RVPH) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.
Lantern Pharma is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Reviva Pharmaceuticals' return on equity of -34.11% beat Lantern Pharma's return on equity.
Reviva Pharmaceuticals has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.
Reviva Pharmaceuticals presently has a consensus target price of $16.75, suggesting a potential upside of 343.12%. Given Lantern Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Reviva Pharmaceuticals is more favorable than Lantern Pharma.
63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 31.8% of Reviva Pharmaceuticals shares are owned by insiders. Comparatively, 6.9% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Reviva Pharmaceuticals had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 8 mentions for Reviva Pharmaceuticals and 6 mentions for Lantern Pharma. Reviva Pharmaceuticals' average media sentiment score of 0.36 beat Lantern Pharma's score of 0.15 indicating that Lantern Pharma is being referred to more favorably in the news media.
Reviva Pharmaceuticals received 2 more outperform votes than Lantern Pharma when rated by MarketBeat users. Likewise, 87.50% of users gave Reviva Pharmaceuticals an outperform vote while only 80.00% of users gave Lantern Pharma an outperform vote.
Summary
Reviva Pharmaceuticals beats Lantern Pharma on 9 of the 15 factors compared between the two stocks.
Get Lantern Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Lantern Pharma Competitors List
Related Companies and Tools